Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback